Fig. 4.

GATA1 inhibits LUAD cisplatin resistance by activating HSD17B6 via DNA damage. A, B qRT-PCR and WB was used to detect the expression of HSD17B6 in A549 cells in each treatment group; C CCK-8 was used to detect the viability of A549 cells in each treatment group; D, E FCM was used to detect the number of cells in G1, S and G2/M phases in each treatment group; F CCK-8 was used to detect the IC₅₀ value of each treatment group treated with gradient concentrations of cisplatin; G Comet assay was used to detect DNA damage in each group of cells treated with PBS and semi-inhibitory concentration of cisplatin; H WB was used to detect the expression of DNA damage-related proteins in cells of each treatment group. * means P < 0.05